pharmaphorum1d
CRISPR biotech Intellia cuts staff as it eyes 2027 launch
In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...
FierceBiotech1d
Intellia, citing 'challenging market environment,' lays off 27% of staff as it takes ax to pipeline
Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...
STAT1d
Intellia cuts 27% of staff, in the latest wave of gene-editing layoffs
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Gene editing stocks drop as Intellia announces layoffs
Shares of gene editing companies dropped on Friday as Wall Street reacted to Intellia Therapeutics' (NASDAQ:NTLA) plans to ...
Strategic Focus and Financial Resilience: Terence Flynn’s Positive Outlook on Intellia Therapeutics
Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), retaining the price target ...
Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where ...
Intellia Therapeutics Restructures to Focus on Late-Stage Programs
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass, Jan. 06, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on ...
Yahoo Finance12d
Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against the other ...